Medicago Inc. (TSX : MDG.TO), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it plans to invest approximately $4 million to enhance the capacity of the pilot production facility located in Quebec City. The Company expects this investment to accelerate preclinical and clinical development timelines of future product candidates. This new investment includes capital expenditures and labour costs, as well as preclinical studies for a rabies vaccine and other products. "Investing in our Quebec City facility is an important step for Medicago as we look towards expanding our product candidate pipeline," said Andrew Sheldon, President and CEO of Medicago. "We are happy to invest in our local community with the addition of approximately 20 new employees in 2012." "We would like to thank CQDM for their past support of the VLPExpress™ platform, which has...
- IRGnews